orantinib has been researched along with su 11248 in 9 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (su 11248) | Trials (su 11248) | Recent Studies (post-2010) (su 11248) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 4,338 | 560 | 3,200 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Chu, JY; Cui, J; Fukuda, JY; Liang, C; Luu, TC; Miller, T; Nematalla, A; Shirazian, S; Sistla, A; Sun, L; Tang, C; Tang, F; Wang, X; Wei, J; Zhou, Y | 1 |
| Gangjee, A; Ihnat, MA; Kurup, S; Shenoy, SS; Thorpe, JE | 1 |
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Kisliuk, RL; Thorpe, JE; Zhao, Y | 1 |
| Aftab, DT; Bentzien, F; Chen, J; Cheng, W; Co, EW; Engst, S; Goon, L; Kim, MH; Klein, RR; Lamb, P; Le, DT; Mac, M; Nuss, JM; Parks, JJ; Qian, F; Rodriquez, M; Stout, TJ; Till, JH; Tsuhako, AL; Won, KA; Wu, X; Xu, W; Yakes, FM; Yu, P; Zhang, W; Zhao, Y | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Béni, S; Boros, S; Breza, N; Dobos, J; Horváth, Z; Illyés, E; Kok, RJ; Nemes, Z; Őrfi, L; Szántai-Kis, C; Szokol, B; Takács-Novák, K; Valko, K; Völgyi, G | 1 |
| Fu, A; Hallahan, DE; Huamani, J; Kim, DW | 1 |
| Chung, HK; Hwang, JH; Jo, KW; Jo, YS; Jung, HS; Kim, DW; Kweon, GR; Lee, SJ; Park, KC; Park, SH; Rha, SY; Shong, M; Song, JH | 1 |
| Stang, JL; Tran, LM; Zhong, H | 1 |
9 other study(ies) available for orantinib and su 11248
| Article | Year |
|---|---|
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosi
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Biological Availability; Enzyme Inhibitors; Indoles; Mice; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solubility; Structure-Activity Relationship; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Diamines; Indoles; Male; Melanoma; Mice; Mice, Nude; Molecular Structure; Phosphorylation; Pyrimidines; Pyrimidinones; Pyrroles; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indenes; Melanoma, Experimental; Mice; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2012 |
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.
Topics: Animals; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Cytochrome P-450 CYP3A; Drug Design; Female; Half-Life; Humans; Indoles; Lung; Mice; Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Rats; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Transplantation, Heterologous | 2012 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML.
Topics: Amino Acids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Structure; Protein Kinase Inhibitors; Solubility; Structure-Activity Relationship; Sunitinib; Tandem Repeat Sequences | 2018 |
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
Topics: Angiogenesis Inhibitors; Animals; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Neoplasms; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propionates; Pyrroles; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2006 |
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Indoles; Mice; NIH 3T3 Cells; Oxindoles; Phosphorylation; Propionates; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrroles; STAT3 Transcription Factor; Sunitinib | 2006 |
Induced-fit docking studies of the active and inactive states of protein tyrosine kinases.
Topics: Binding Sites; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Hydrogen Bonding; Indoles; Ligands; Models, Molecular; Oxindoles; Propionates; Protein Structure, Secondary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrroles; Quinazolines; Reproducibility of Results; Sunitinib | 2009 |